AR882 is an investigational selective uric acid transporter 1 inhibitor. The Food and Drug Administration (FDA) has granted Fast Track designation to AR882 for the treatment of clinically visible ...

The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout. Over 12 months, ...

Background A 56-year-old white woman was referred to our institution with a 16-month history of severe, gouty, recurrent, acute polyarthritis involving the finger joints. She also had numerous small ...

The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout. Over 12 months, ...

The characteristics of the sample are presented in Table 1 and Table 2. The average age was 60.9 years, and patients had been diagnosed an average of 12 years. Most were male (81%), and 38% were ...

US-based biotechnology company Arthrosi Therapeutics has completed a series E funding round, amassing $153m which is earmarked to advance the clinical development of its flagship programme, ...

Pegloticase quickly resolved tophi among patients with gout who responded to the treatment, according to data published in Arthritis Research & Therapy. “Pegloticase is a recombinant mammalian uricase ...

Chronic tophaceous gout (CTG) is an independent risk factor for colorectal cancer (CRC), according to study results presented at Digestive Disease Week (DDW), held from May 6 to 9, 2023 in Chicago, ...

The drug lesinurad in combination with febuxostat was better at lowering blood levels of urate than febuxostat alone in a phase III clinical trial of 324 patients with tophaceous gout. Over 12 months, ...

Background A 56-year-old white woman was referred to our institution with a 16-month history of severe, gouty, recurrent, acute polyarthritis involving the finger joints. She also had numerous small ...